Journal of Neural Transmission

, Volume 114, Issue 7, pp 919–927 | Cite as

Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?

  • B. Mollenhauer
  • M. Bibl
  • H. Esselmann
  • P. Steinacker
  • C. Trenkwalder
  • J. Wiltfang
  • M. Otto
Article

Summary

To evaluate variations in amyloid beta (Aβ) peptide pattern in cerebrospinal fluid (CSF) in neurodegenerative disorders. A recently established quantitative urea-based Aβ-sodium-dodecylsulfate-polyacrylamide-gel-electrophoresis with western immunoblot (Aβ-SDS-PAGE/immunoblot) revealed a highly conserved Aβ peptide (Aβ1-37, 1-38, 1-39, 1-40, 1-42) pattern in CSF. We asked whether the variation might be useful to further elucidate the overlap between or distinctions among neurodegenerative diseases in Aβ-processing.

We used the Aβ-SDS-PAGE/immunoblot to investigate CSF for disease-specific Aβ peptide patterns. CSF samples from 96 patients with mainly clinically diagnosed Alzheimer’s disease (n = 15), progressive supranuclear palsy (n = 20), corticobasal degeneration (n = 12), Parkinson’s disease (n = 11), multiple systems atrophy (n = 18), and dementia with Lewy-bodies (n = 20) were analysed as well a comparison group (n = 19).

The Aβ peptide patterns varied between tauopathies and synucleinopathies and between all diseases and the comparison group, possibly due to the influence of tau and α-synuclein on Aβ-processing.

Keywords: Synucleinopathies, tauopathies, Alzheimer’s disease, Parkinson’s disease, cerebrospinal fluid, amyloid β peptides 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreasen, N, Blennow, K 2002Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer’s diseasePeptides2312051214PubMedCrossRefGoogle Scholar
  2. Bibl, M, Esselmann, H, Otto, M, Lewczuk, P, Cepek, L, Ruther, E, Kornhuber, J, Wiltfang, J 2004Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptidesElectrophoresis2529122918PubMedCrossRefGoogle Scholar
  3. Bibl, M, Mollenhauer, B, Esselmann, H, Lewczuk, P, Klafki, H-W, Sparbier, K, Smirnov, A, Cepek, L, Trenkwalder, C, Ruther, E, Kornhuber, J, Otto, M, Wiltfang, J 2006CSF amyloid-{beta}-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementiaBrain12911771187PubMedCrossRefGoogle Scholar
  4. Bloom, GS, Ren, K, Glabe, CG 2005Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloidBiochim Biophys Acta1739116124PubMedGoogle Scholar
  5. Citron, M, Diehl, TS, Gordon, G, Biere, AL, Seubert, P, Selkoe, DJ 1996Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activitiesProc Natl Acad Sci USA931317013175PubMedCrossRefGoogle Scholar
  6. Clark, CM, Xie, S, Chittams, J, Ewbank, D, Peskind, E, Galasko, D, Morris, JC, McKeel, DW,Jr, Farlow, M, Weitlauf, SL, Quinn, J, Kaye, J, Knopman, D, Arai, H, Doody, RS, DeCarli, C, Leight, S, Lee, VM, Trojanowski, JQ 2003Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?Arch Neurol6016961702PubMedCrossRefGoogle Scholar
  7. Clarke, CE 2004Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s diseaseLancet Neurol3466474PubMedCrossRefGoogle Scholar
  8. Culvenor, JG, McLean, CA, Cutt, S, Campbell, BC, Maher, F, Jakala, P, Hartmann, T, Beyreuther, K, Masters, CL, Li, QX 1999Non-Abeta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloidAm J Pathol15511731181PubMedGoogle Scholar
  9. El-Agnaf, OM, Salem, SA, Paleologou, KE, Cooper, LJ, Fullwood, NJ, Gibson, MJ, Curran, MD, Court, JA, Mann, DM, Ikeda, S, Cookson, MR, Hardy, J, Allsop, D 2003Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasmaFASEB1719451947Google Scholar
  10. Faghan, AM, Mintun, MA, Mach, RH, Sang-Yoon, L, Dence, CS, Shah, AR, LaRossa, GN, Spinner, ML, Klunk, WE, Mathis, CA, DeKosky, ST, Morris, JC, Holtzman, DM 2006Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humansAnn Neurol59512519CrossRefGoogle Scholar
  11. Folstein, MF, Folstein, SE, McHugh, PR 1975“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res12189198PubMedCrossRefGoogle Scholar
  12. Frank, RA, Galasko, D, Hampel, H, Hardy, J, de Leon, MJ, Mehta, PD, Rogers, J, Siemers, E, Trojanowski, JQ 2003Biological markers for therapeutic trials in Alzheimer’s disease. Proc., Biological Markers Working Group; NIA initiative on neuroimaging in Alzheimer’s diseaseNeurobiol Aging24521536PubMedCrossRefGoogle Scholar
  13. Gilman, S, Low, P, Quinn, N, Albanese, A, Ben-Shlomo, Y, Fowler, C, Kaufmann, H, Klockgether, T, Lang, A, Lantos, P, Litvan, I, Mathias, C, Oliver, E, Robertson, D, Schatz, I, Wenning, G 1998Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of NeurologyClin Auton Res8359362PubMedCrossRefGoogle Scholar
  14. Glenner, GG, Wong, CW, Quaranta, V, Eanes, ED 1984The amyloid deposits in Alzheimer’s disease: their nature and pathogenesisAppl Pathol2357369PubMedGoogle Scholar
  15. Gomez-Tortosa, E, Gonzalo, I, Fanjul, S, Sainz, MJ, Cantarero, S, Cemillan, C, Yebenes, JG, del Ser, T 2003Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer diseaseArch Neurol6012181222PubMedCrossRefGoogle Scholar
  16. Guo, JP, Arai, T, Miklossy, J, McGeer, PL 2006Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble form observed in Alzheimer’s diseaseProc Natl Acad Sci USA10319531958PubMedCrossRefGoogle Scholar
  17. Haass, C, Selkoe, DJ 1993Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptideCell7510391042PubMedCrossRefGoogle Scholar
  18. Hardy, J, Selkoe, DJ 2002The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience297353356PubMedCrossRefGoogle Scholar
  19. Holmberg, B, Johnels, B, Blennow, K, Rosengren, L 2003Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsyMov Disord18186190PubMedCrossRefGoogle Scholar
  20. Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ 1992Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 casesJ Neurol Neurosurg Psychiatry55181184PubMedCrossRefGoogle Scholar
  21. Hulstaert, F, Blennow, K, Ivanoiu, A, Schoonderwaldt, HC, Riemenschneider, M, De Deyn, PP, Bancher, C, Cras, P, Wiltfang, J, Mehta, PD, Iqbal, K, Pottel, H, Vanmechelen, E, Vanderstichele, H 1999Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSFNeurology5215551562PubMedGoogle Scholar
  22. Iwai, A, Yoshimoto, M, Masliah, E, Saitoh, T 1995Non-A beta component of Alzheimer’s disease amyloid (NAC) is amyloidogenicBiochemistry341013910145PubMedCrossRefGoogle Scholar
  23. Janek, K, Rothemund, S, Gast, K, Beyermann, M, Zipper, J, Fabian, H, Bienert, M, Krause, E 2001Study of the conformational transition of A beta(1-42) using D-amino acid replacement analoguesBiochemistry4054575463PubMedCrossRefGoogle Scholar
  24. Jellinger, KA 2003Prevalence of Alzheimer lesions in Parkinson’s diseaseMov Disord1812071208PubMedCrossRefGoogle Scholar
  25. Jendroska, K, Lees, AJ, Poewe, W, Daniel, SE 1996Amyloid beta-peptide and the dementia of Parkinson’s diseaseMov Disord11647653PubMedCrossRefGoogle Scholar
  26. Jendroska, K, Kashiwagi, M, Sassoon, J, Daniel, SE 1997Amyloid beta-peptide and its relationship with dementia in Lewy body diseaseJ Neural Transm Suppl51137144PubMedGoogle Scholar
  27. Kawooya, JK, Emmons, TL, Gonzalez-DeWhitt, PA, Camp, MC, D’Andrea, SC 2003Electrophoretic mobility of Alzheimer’s amyloid-beta peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresisAnal Biochem323103113PubMedCrossRefGoogle Scholar
  28. Kurosinski, P, Guggisberg, M, Gotz, J 2002Alzheimer’s and Parkinson’s disease–overlapping or synergistic pathologies?Trends Mol Med835PubMedCrossRefGoogle Scholar
  29. Lippa, CF, Ozawa, K, Mann, DM, Ishii, K, Smith, TW, Arawaka, S, Mori, H 1999Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer diseaseArch Neurol5611111118PubMedCrossRefGoogle Scholar
  30. Lippa, SM, Lippa, CF, Mori, H 2005Alpha-Synuclein aggregation in pathological aging and Alzheimer’s disease: the impact of beta-amyloid plaque levelAm J Alzheimers Dis Other Demen20315318PubMedCrossRefGoogle Scholar
  31. Litvan, I 1997Progressive supranuclear palsy and corticobasal degenerationBaill Clin Neurol6167185Google Scholar
  32. Litvan, I, Agid, Y, Goetz, C, Jankovic, J, Wenning, GK, Brandel, JP, Lai, EC, Verny, M, Ray-Chaudhuri, K, McKee, A, Jellinger, K, Pearce, RK, Bartko, JJ 1997aAccuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic studyNeurology48119125Google Scholar
  33. Litvan, I, Goetz, CG, Jankovic, J, Wenning, GK, Booth, V, Bartko, JJ, McKee, A, Jellinger, K, Lai, EC, Brandel, JP, Verny, M, Chaudhuri, KR, Pearce, RK, Agid, Y 1997bWhat is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic studyArch Neurol54937944Google Scholar
  34. Lopez, OL, Litvan, I, Catt, KE, Stowe, R, Klunk, W, Kaufer, DI, Becker, JT, DeKosky, ST 1999Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementiasNeurology5312921299PubMedGoogle Scholar
  35. Lopez, OL, Becker, JT, Kaufer, DI, Hamilton, RL, Sweet, RA, Klunk, W, DeKosky, ST 2002Research evaluation and prospective diagnosis of dementia with Lewy bodiesArch Neurol594346PubMedCrossRefGoogle Scholar
  36. Marui, W, Iseki, E, Kato, M, Akatsu, H, Kosaka, K 2004Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s diseaseActa Neuropathol (Berl)108121128Google Scholar
  37. Masliah, E, Iwai, A, Mallory, M, Ueda, K, Saitoh, T 1996Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s diseaseAm J Pathol148201210PubMedGoogle Scholar
  38. Mastaglia, FL, Johnsen, RD, Byrnes, ML, Kakulas, BA 2003Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s diseaseMov Disord188186PubMedCrossRefGoogle Scholar
  39. McKeith, IG, Galasko, D, Kosaka, K, Perry, EK, Dickson, DW, Hansen, LA, Salmon, DP, Lowe, J, Mirra, SS, Byrne, EJ, Lennox, G, Quinn, NP, Edwardson, JA, Ince, PG, Bergeron, C, Burns, A, Miller, BL, Lovestone, S, Collerton, D, Jansen, EN, Ballard, C, de Vos, RA, Wilcock, GK, Jellinger, KA, Perry, RH 1996Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopNeurology4711131124PubMedGoogle Scholar
  40. McKeith, IG Dickson, DW Lowe, J Emre, M O’Brien, JT Feldman, H Cummings, J Duda, JE Lippa, C Perry, EK Aarsland, D Arai, H Ballard, CG Boeve, B Burn, DJ Costa, D Del Ser, T Dubois, B Galasko, D Gauthier, S Goetz, CG Gomez-Tortosa, E Halliday, G Hansen, LA Hardy, J Iwatsubo, T Kalaria, RN Kaufer, D Kenny, RA Korczyn, A Kosaka, K Lee, VMY Lees, A Litvan, I Londos, E Lopez, OL Minoshima, S Mizuno, Y Molina, JA Mukaetova-Ladinska, EB Pasquier, F Perry, RH Schulz, JB Trojanowski, JQ Yamada, M for the Consortium on DLB2005Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortiumNeurology6518631872PubMedCrossRefGoogle Scholar
  41. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM 1984Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s diseaseNeurology34939944PubMedGoogle Scholar
  42. Mehta, P, Pirttila, T 2005Increased cerebrospinal fluid Aβ38/Aβ42 ratio in Alzheimer diseaseNeurodegen Dis2242245CrossRefGoogle Scholar
  43. Merdes, AR, Hansen, LA, Jeste, DV, Galasko, D, Hofstetter, CR, Ho, GJ, Thal, LJ, Corey-Bloom, J 2003Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodiesNeurology6015861590PubMedGoogle Scholar
  44. Mollenhauer B, Cullen V, Krastins B, Trenkwalder C, Sarracino DA, Schlossmacher H (2006) Characterisation and quantification of α-synuclein release into cell cultured medium and cerebrospinal fluid. Mov Disord 21 Suppl 15 (72)Google Scholar
  45. Mori, H, Oda, M, Komori, T, Arai, N, Takanashi, M, Mizutani, T, Hirai, S, Mizuno, Y 2002Lewy bodies in progressive supranuclear palsyActa Neuropathol (Berl)104273278Google Scholar
  46. Motter, R, Vigo-Pelfrey, C, Kholodenko, D, Barbour, R, Johnson-Wood, K, Galasko, D, Chang, L, Miller, B, Clark, C, Green, R,  et al. 1995Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s diseaseAnn Neurol38643648PubMedCrossRefGoogle Scholar
  47. Noguchi, M, Yoshita, M, Matsumoto, Y, Ono, K, Iwasa, K, Yamada, M 2005Decreased beta-amyloid peptide(42) in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degenerationJ Neurol Sci2376165PubMedCrossRefGoogle Scholar
  48. Otto, M, Esselmann, H, Schulz-Shaeffer, W, Neumann, M, Schroter, A, Ratzka, P, Cepek, L, Zerr, I, Steinacker, P, Windl, O, Kornhuber, J, Kretzschmar, HA, Poser, S, Wiltfang, J 2000Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseaseNeurology5410991102PubMedGoogle Scholar
  49. Paik, SR, Lee, JH, Kim, DH, Chang, CS, Kim, YS 1998Self-oligomerization of NACP the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer’s disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25–35)FEBS Lett4217376PubMedCrossRefGoogle Scholar
  50. Palmblad, M, Westlind-Danielsson, A, Bergquist, J 2002Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1-40 oligomersJ Biol Chem2771950619510PubMedCrossRefGoogle Scholar
  51. Parkkinen, L, Kauppinen, T, Pirttila, T, Autere, JM, Alafuzoff, I 2005Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementiaAnn Neurol578291PubMedCrossRefGoogle Scholar
  52. Pletnikova, O, West, N, Lee, MK, Rudow, GL, Skolasky, RL, Dawson, TM, Marsh, L, Troncoso, JC 2005A[beta] deposition is associated with enhanced cortical [alpha]-synuclein lesions in Lewy body diseasesNeurobiol Aging2611831192PubMedCrossRefGoogle Scholar
  53. Primavera, J, Lu, BX, Riskind, PJ, Iulian, M, De La Monte, SM 1999Brain accumulation of amyloid-beta in non-Alzheimer neurodegenerationJ Alzheimers Dis1183193PubMedGoogle Scholar
  54. Quinn, NP 2005How to diagnose multiple system atrophyMov Disord20S5S10PubMedCrossRefGoogle Scholar
  55. Ribe, EM, Perez, M, Puig, B, Gich, I, Lim, F, Cuadrado, M, Sesma, T, Catena, S, Sanchez, B, Nieto, M 2005Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic miceNeurobiol Dis20814822PubMedCrossRefGoogle Scholar
  56. Sasaki, S, Maruyama, S, Toyoda, C 1991A case of progressive supranuclear palsy with widespread senile plaquesJ Neurol238345348PubMedCrossRefGoogle Scholar
  57. Schlossmacher MG (2006) Monitoring of alpha-synuclein steady-state levels in vivo by ELISA. Mov Disord 21 Suppl 13 (026)Google Scholar
  58. Schneider, JA, Watts, RL, Gearing, M, Brewer, RP, Mirra, SS 1997Corticobasal degeneration: neuropathologic and clinical heterogeneityNeurology48959969PubMedGoogle Scholar
  59. Spillantini, MG, Schmidt, ML, Lee, VM, Trojanowski, JQ, Jakes, R, Goedert, M 1997Alpha-synuclein in Lewy bodiesNature388839840PubMedCrossRefGoogle Scholar
  60. Strozyk, D, Blennow, K, White, LR, Launer, LJ 2003CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy studyNeurology60652656PubMedGoogle Scholar
  61. Suh, YH, Checler, F 2002Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s diseasePharmacol Rev54469525PubMedCrossRefGoogle Scholar
  62. Takeda, A, Mallory, M, Sundsmo, M, Honer, W, Hansen, L, Masliah, E 1998Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disordersAm J Pathol152367372PubMedGoogle Scholar
  63. Uchikado H, Delledonne A, Uitti R, Dickson DW (2006) Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol (Berl): 1–7Google Scholar
  64. Urasaki, K, Kuriki, K, Namerikawa, M, Satoh, S, Ikeguchi, K, Fukayama, M, Saito, K, Nakano, I 2000An autopsy case of Alzheimer’s disease with a progressive supranuclear palsy overlapNeuropathology20233238PubMedCrossRefGoogle Scholar
  65. Verbeek, MM, Abdo, WF, De Jong, D, Horstink, MW, Kremer, BP, Bloem, BR 2004Cerebrospinal fluid Abeta42 levels in multiple system atrophyMov Disord19238240author reply 240–241PubMedCrossRefGoogle Scholar
  66. Wiltfang, J, Smirnov, A, Schnierstein, B, Kelemen, G, Matthies, U, Klafki, HW, Staufenbiel, M, Huther, G, Ruther, E, Kornhuber, J 1997Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43Electrophoresis18527532PubMedCrossRefGoogle Scholar
  67. Wiltfang, J, Esselmann, H, Cupers, P, Neumann, M, Kretzschmar, H, Beyermann, M, Schleuder, D, Jahn, H, Ruther, E, Kornhuber, J, Annaert, W, De Strooper, B, Saftig, P 2001Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cellsJ Biol Chem2764264542657PubMedCrossRefGoogle Scholar
  68. Wiltfang, J, Esselmann, H, Bibl, M, Smirnov, A, Otto, M, Paul, S, Schmidt, B, Klafki, HW, Maler, M, Dyrks, T, Bienert, M, Beyermann, M, Ruther, E, Kornhuber, J 2002Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammationJ Neurochem81481496PubMedCrossRefGoogle Scholar
  69. Wiltfang, J, Esselmann, H, Smirnov, A, Bibl, M, Cepek, L, Steinacker, P, Mollenhauer, B, Buerger, K, Hampel, H, Paul, S, Neumann, M, Maler, M, Zerr, I, Kornhuber, J, Kretzschmar, HA, Poser, S, Otto, M 2003Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseaseAnn Neurol54263267PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • B. Mollenhauer
    • 1
  • M. Bibl
    • 2
  • H. Esselmann
    • 3
  • P. Steinacker
    • 4
  • C. Trenkwalder
    • 5
  • J. Wiltfang
    • 3
  • M. Otto
    • 4
  1. 1.Brigham and Women’s Hospital and Harvard Medical SchoolBostonU.S.A.
  2. 2.Department of PsychiatryUniversity of GoettingenGoettingenGermany
  3. 3.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany
  4. 4.Department of NeurologyUniversity of UlmUlmGermany
  5. 5.University of Goettingen, Paracelsus-Elena KlinikKasselGermany

Personalised recommendations